Ascendis Pharma A/S (NASDAQ:ASND) CFO Acquires $21,900.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) CFO Scott Thomas Smith purchased 100 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, June 2nd. The shares were acquired at an average cost of $219.00 per share, for a total transaction of $21,900.00. Following the completion of the transaction, the chief financial officer owned 4,367 shares of the company’s stock, valued at approximately $956,373. This represents a 2.34% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ascendis Pharma A/S Stock Down 1.0%

Shares of ASND stock traded down $2.26 during trading hours on Tuesday, reaching $216.56. 662,823 shares of the company’s stock were exchanged, compared to its average volume of 580,270. The stock’s 50 day moving average is $233.43 and its 200-day moving average is $223.39. The company has a market cap of $13.51 billion, a price-to-earnings ratio of 25.58 and a beta of 0.41. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. Analysts predict that Ascendis Pharma A/S will post 11.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently made changes to their positions in the company. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Arax Advisory Partners increased its position in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $42,000. Finally, Jones Financial Companies Lllp boosted its holdings in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ASND. Wolfe Research reaffirmed an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $255.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Stifel Nicolaus set a $332.00 price target on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Morgan Stanley reissued an “overweight” rating and issued a $256.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Finally, Bank of America upped their target price on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $295.39.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.